Cell Therapeutics (CTIC) Posts Narrower Q1 Loss of 9c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CTIC Hot Sheet
Price: $9.09 --0%
Financial Fact:
Foreign exchange gain (loss): -69K
Today's EPS Names:
CRVL, DD, ARDS, More
Financial Fact:
Foreign exchange gain (loss): -69K
Today's EPS Names:
CRVL, DD, ARDS, More
Join SI Premium – FREE
Cell Therapeutics Inc. (NASDAQ: CTIC) reported Q1 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10).
For earnings history and earnings-related data on Cell Therapeutics Inc. (CTIC) click here.
For earnings history and earnings-related data on Cell Therapeutics Inc. (CTIC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SOPHiA GENETICS SA (SOPH) Misses Q3 EPS by 6c; Offers Guidance
- Dynatrace Inc. (DT) Tops Q2 EPS by 5c ; Offers Guidance
- Archer Daniels Midland (ADM) Tops Q3 EPS by 20c; raises guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
